We observed a decrease in the expression/levels of Erk1/2, p-Erk1/2, and CDK4/6 in MM-cells treated with Erk1/2i + CDK4/6i compared to cells treated with either single agent. The gene discussed is MAPK3; the disease is Miyoshi myopathy.